WES was performed on one fresh-frozen and five formalin-fixed paraffin-embedded (FFPE) samples from Patient 1 (P1), on six FFPE samples from Patient 2 (P2), and on benign FFPE tissue for both patients (germline control). We used a previously described (Rennert et al. 2016 (link); Beltran et al. 2015 (link)) clinical-grade WES test (EXaCT-1). Briefly, DNA was extracted using Promega Maxwell 16 MDX. Libraries were constructed using targeted capture of 21,522 genes with the HaloPlex System (Agilent), followed by paired-end 2 × 100 bp sequencing with Illumina HiSeq2500, for an intended mean target exome coverage of 80× for both the tumor and the germline samples. Reads were aligned to the human genome (reference GRC37/hg19) and data were analyzed using an internally developed pipeline (Rennert et al. 2016 (link)).